These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 19934334)

  • 1. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-targeting fusion constructs containing recombinant gelonin.
    Lyu MA; Cao YJ; Mohamedali KA; Rosenblum MG
    Methods Enzymol; 2012; 502():167-214. PubMed ID: 22208986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
    Rosenblum MG; Cheung LH; Liu Y; Marks JW
    Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin.
    Cizeau J; Grenkow DM; Brown JG; Entwistle J; MacDonald GC
    J Immunother; 2009; 32(6):574-84. PubMed ID: 19483652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
    Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
    Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
    Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells.
    Ren JL; Meng YL; Hu B; Jia LT; Zhang R; Xu YM; Xie QS; Zhang YQ; Jin BQ; Chen SY; Wang T; Yang AG
    Biomaterials; 2011 Oct; 32(30):7641-50. PubMed ID: 21767874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
    Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
    Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.